210 related articles for article (PubMed ID: 35023119)
1. Advanced Health Technologies and Nanotechnologies in Neurodegenerative Diseases.
Naziris N; Demetzos C
Adv Exp Med Biol; 2021; 1339():317. PubMed ID: 35023119
[TBL] [Abstract][Full Text] [Related]
2. The Regulatory Landscape of New Health Technologies and Nanotechnologies: The Role of Complexity of Nanosystems.
Naziris N; Demetzos C
Adv Exp Med Biol; 2023; 1425():575-589. PubMed ID: 37581831
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes.
Dri DA; Rinaldi F; Carafa M; Marianecci C
Drug Deliv Transl Res; 2023 Mar; 13(3):757-769. PubMed ID: 36450964
[TBL] [Abstract][Full Text] [Related]
4. Nanotechnology-empowered therapeutics targeting neurodegenerative diseases.
Wang Z; Gonzalez KM; Cordova LE; Lu J
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1907. PubMed ID: 37248794
[TBL] [Abstract][Full Text] [Related]
5. Nanomedicines: addressing the scientific and regulatory gap.
Tinkle S; McNeil SE; Mühlebach S; Bawa R; Borchard G; Barenholz YC; Tamarkin L; Desai N
Ann N Y Acad Sci; 2014 Apr; 1313():35-56. PubMed ID: 24673240
[TBL] [Abstract][Full Text] [Related]
6. Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation.
Halamoda-Kenzaoui B; Vandebriel RJ; Howarth A; Siccardi M; David CAW; Liptrott NJ; Santin M; Borgos SE; Bremer-Hoffmann S; Caputo F
J Control Release; 2021 Aug; 336():192-206. PubMed ID: 34126169
[TBL] [Abstract][Full Text] [Related]
7. Nanotechnology: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
[TBL] [Abstract][Full Text] [Related]
8. Nanosimilars: A Scientific or A Regulatory Debate?
Demetzos C
AAPS J; 2024 Jul; 26(4):74. PubMed ID: 38955936
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicines and Nanosimilars: Looking for a New and Dynamic Regulatory "Astrolabe" Inspired System.
Demetzos C; Kavatzikidou P; Pippa N; Stratakis E
AAPS PharmSciTech; 2020 Jan; 21(2):65. PubMed ID: 31933006
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnology and antioxidant therapy: an emerging approach for neurodegenerative diseases.
Fernandes C; Oliveira C; Benfeito S; Soares P; Garrido J; Borges F
Curr Med Chem; 2014; 21(38):4311-27. PubMed ID: 25245378
[TBL] [Abstract][Full Text] [Related]
11. Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges.
Musazzi UM; Franzè S; Condorelli F; Minghetti P; Caliceti P
Adv Healthc Mater; 2023 Dec; 12(30):e2301956. PubMed ID: 37718353
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicines: The magic bullets reaching their target?
Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
[TBL] [Abstract][Full Text] [Related]
13. Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape.
Paliwal R; Kumar P; Chaurasiya A; Kenwat R; Katke S; Paliwal SR
Curr Pharm Des; 2022; 28(2):165-177. PubMed ID: 34781869
[TBL] [Abstract][Full Text] [Related]
14. Application of Proteomic Tools in Modern Nanotechnological Approaches Towards Effective Management of Neurodegenerative Disorders.
Ali A; Sheikh IA; Mirza Z; Gan SH; Kamal MA; Abuzenadah AM; Damanhouri GA; Ashraf GM
Curr Drug Metab; 2015; 16(5):376-88. PubMed ID: 25495738
[TBL] [Abstract][Full Text] [Related]
15. Physical-, chemical-, and biological-responsive nanomedicine for cancer therapy.
Liao J; Jia Y; Wu Y; Shi K; Yang D; Li P; Qian Z
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jan; 12(1):e1581. PubMed ID: 31429208
[TBL] [Abstract][Full Text] [Related]
16. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
Foffi G; Pastore A; Piazza F; Temussi PA
Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicine Approaches for Advanced Diagnosis and Treatment of Atherosclerosis and Related Ischemic Diseases.
Hu B; Boakye-Yiadom KO; Yu W; Yuan ZW; Ho W; Xu X; Zhang XQ
Adv Healthc Mater; 2020 Aug; 9(16):e2000336. PubMed ID: 32597562
[TBL] [Abstract][Full Text] [Related]
18. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
Mühlebach S
Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
[TBL] [Abstract][Full Text] [Related]
19. [Nanomedicine: application of nanotechnology in medicine. Opportunities in neuropsychiatry].
Szebeni J
Neuropsychopharmacol Hung; 2011 Mar; 13(1):15-24. PubMed ID: 21451188
[TBL] [Abstract][Full Text] [Related]
20. [Nanomedicine as a part of nanotechnology].
Piotrovskiĭ LB
Vestn Ross Akad Med Nauk; 2010; (3):41-6. PubMed ID: 20420215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
